-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, another company will enter the PPI large variety lansoprazole
Figure 1: The registration progress of lansoprazole for injection of Poinsettia
Source: NMPA official website
Lansoprazole is the first-generation PPI preparation, and its bioavailability is 30% higher than that of omeprazole, and it inhibits gastric acid secretion by 2-10 times
Figure 2: The formulation of Lansoprazole
Source: Mi Nei.
At present, the products involved in Lansoprazole include enteric-coated capsules, capsules, ordinary tablets, orally disintegrating tablets, and enteric-coated tablets.
Figure 3: The situation of companies that have been reviewed/deemed to have reviewed lansoprazole for injection
Source: Mi Nei Net Consistency Evaluation Database
There are more than 30 domestic companies with approvals for lansoprazole for injection, but only 6 companies have been reviewed.
Source: NMPA official website, Minet database
The review data statistics are as of November 2.